Endothelial-cardiomyocyte crosstalk enhances pharmacological cardioprotection

Thorsten M Leucker1, Martin Bienengraeber, Maria Muravyeva

  • 1Department of Anesthesiology Medical College of Wisconsin, Milwaukee, WI, USA.

Insights

Isoflurane-stimulated endothelial cells protect heart cells from injury by releasing nitric oxide. This effect is mediated by hypoxia-inducible factor 1-alpha, offering potential for treating ischemia-reperfusion injury.

Area of Science:

  • Cardiovascular Biology
  • Cellular Physiology
  • Pharmacology

Background:

  • Endothelial cells (EC) and cardiomyocytes (CM) interact, influencing each other's function.
  • EC may play a role in protecting CM during ischemia-reperfusion (I/R) injury.
  • Pharmacological agents can induce cardioprotection, often involving nitric oxide (NO) pathways.

Purpose of the Study:

  • To investigate if EC contribute to isoflurane-enhanced protection of CM against hypoxia and reoxygenation (H/R) injury.
  • To determine if this EC-mediated protection depends on hypoxia-inducible factor 1-alpha (HIF1α) and NO.
  • To explore the role of EC in modulating mitochondrial integrity during H/R injury.

Main Methods:

  • Co-culture of EC and CM subjected to H/R injury.
  • Assessment of CM injury via lactate dehydrogenase (LDH) release.
  • Measurement of NO production in EC and co-cultures.
  • HIF1α knockdown in EC using lentiviral vectors.
  • Evaluation of mitochondrial permeability transition pore (mPTP) opening.
  • Analysis of HIF1α expression and activation using Western blot and immunofluorescence.

Main Results:

  • EC significantly protected CM against H/R injury, an effect dependent on NO.
  • Isoflurane increased NO release from EC and sustained NO release during reoxygenation in co-cultures.
  • HIF1α knockdown in EC reduced basal and isoflurane-stimulated NO release and prevented sustained NO release during reoxygenation.
  • EC presence delayed mPTP opening, indicating preserved mitochondrial integrity.
  • Isoflurane increased HIF1α in EC, an effect mediated by the MAPK/ERK pathway.

Conclusions:

  • EC contribute to isoflurane-induced cardioprotection against H/R injury.
  • This protection is mediated by NO production, which is regulated by HIF1α in EC.
  • EC safeguard mitochondrial function during H/R injury, potentially via HIF1α-dependent NO signaling.

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...